Printer Friendly

Karin Hoogendoorn appointed as Immunicum AB's head of CMC.

M2 PHARMA-February 13, 2017-Karin Hoogendoorn appointed as Immunicum AB's head of CMC

(C)2017 M2 COMMUNICATIONS

Immunicum AB (First North Premier: IMMU.ST) has appointed Karin Hoogendoorn as its head of Chemistry, Manufacturing and Controls (CMC), the company said on Monday.

Hoogendoorn will be bringing 20 years of experience within the biotechnology and pharmaceutical industry when she joins the company.

Her most recent role has seen her serve as associate director regulatory CMC in the Cell and Gene therapy unit at Novartis AG (VTX: NOVN). Here, Hoogendoorn was in charge of global regulatory CMC as well as overall CMC strategy for cell and gene therapies.

Hoogendoorn worked at Janssen Biologics BV (previously known as Centocor BV) as associate director of global regulatory affairs - CMC. It was her responsibility to write and review quality sections of regulatory dossiers for advanced medicinal products, such as cell based medicinal products and combination products, as well as monoclonal antibodiess.

Hoogendoorn has also held numerous CMC roles at companies such as Crucell Holland BV and OctoPlus Development BV.

Alongside her role at Immunicum, Hoogendoorn serves as senior consultant CMC and CMC-RA at Quality RA BV in Leiden, the Netherlands.

((Comments on this story may be sent to info@m2.com))

COPYRIGHT 2017 Normans Media Ltd.
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 2017 Gale, Cengage Learning. All rights reserved.

Article Details
Printer friendly Cite/link Email Feedback
Publication:M2 Pharma
Date:Feb 13, 2017
Words:205
Previous Article:Intellipharmaceutics incurs higher net loss of USD10.1m for 2016.
Next Article:Hepatitis C market expected to shrink.
Topics:

Terms of use | Privacy policy | Copyright © 2019 Farlex, Inc. | Feedback | For webmasters